Shares of Geron Corp. (NASDAQ:GERN) shot up 1.8% during trading on Wednesday . The stock traded as high as $2.80 and last traded at $2.78, with a volume of 786,227 shares trading hands. The stock had previously closed at $2.73.

Several brokerages have issued reports on GERN. BTIG Research began coverage on Geron Corp. in a research report on Friday, August 19th. They issued a “neutral” rating for the company. Zacks Investment Research downgraded Geron Corp. from a “hold” rating to a “sell” rating in a research report on Tuesday, May 10th. Finally, FBR & Co reiterated a “buy” rating on shares of Geron Corp. in a research report on Sunday, May 8th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $6.20.

The firm has a 50 day moving average price of $2.70 and a 200-day moving average price of $2.81. The stock has a market capitalization of $424.90 million and a P/E ratio of 333.75.

Geron Corp. (NASDAQ:GERN) last issued its quarterly earnings results on Wednesday, August 3rd. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.07) by $0.02. The company had revenue of $0.21 million for the quarter, compared to analyst estimates of $0.38 million. During the same period in the prior year, the company earned ($0.06) EPS. The company’s quarterly revenue was down 15.9% compared to the same quarter last year. Analysts forecast that Geron Corp. will post ($0.23) EPS for the current year.

Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc (Janssen). The Company operates through the segment, which includes discovery and development of therapeutic products for oncology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.